|Ligand Pharmaceuticals Incorporated|
11119 North Torrey Pines Road
United States - Map
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, blood disorders, anti-coagulant, pain, depression, allergy, sun damage, restless leg/parkinson's, cognitive disorders, oncology, and inflammation. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis, Amgen, Inc, Merck & Co., Inc., Pfizer Inc., Celgene, Gilead, Janssen, Baxter International, Inc., and Eli Lilly and Company. The company was founded in 1987 and is headquartered in La Jolla, California.
|Ligand Pharmaceuticals Incorporated’s ISS Governance QuickScore as of Apr 1, 2016 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 6.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. John L. Higgins ,
Chief Exec. Officer and Exec. Director
|Mr. Matthew W. Foehr ,
Pres and Chief Operating Officer
|Mr. Matthew Korenberg ,
Chief Financial Officer and VP of Fin.
|Ms. Melanie J. Herman ,
Chief Accounting Officer
|Mr. Charles S. Berkman J.D.,
VP, Gen. Counsel and Sec.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|